SenseTime, headquartered in Hong Kong, has announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro. Leveraging SenseTime's cutting-edge AI technologies, the solution can quickly triage normal and abnormal scans from chest X-ray screening and accurately detect various chest diseases on the abnormal ones, effectively improving the efficiency of large-scale physical examination and regular clinical diagnosis.
The certification of SenseCare-Chest DR Pro marks another milestone for SenseTime in introducing its AI medical solutions for both computed tomography (CT) and digital radiography (DR) to international markets after its SenseCare-Lung Pro medical solution was granted the CE mark last year.
It means that SenseTime's AI medical solutions can provide comprehensive support with an international standard to medical institutions around the world for chest diseases based on CT and DR imaging modalities.
The large quantity of chest x-rays (CXR) images generated daily leads to the heavy workload of radiologists who need to manually review and analyse the images. Misdiagnosis may also occur due to the high complexity of the body parts screened in CXR, which may present a risk to the health of patients. SenseCare-Chest DR Pro was developed based on SenseTime's proprietary deep-learning technologies. Through learning and training with mass chest X-ray images, the software can quickly classify normal and abnormal CXR images.
Concurrently, it detects and locates lesions or abnormalities for multiple diseases including pneumonia, tuberculosis, pneumothorax, pleural effusion, cardiomegaly, and rib fractures. The software also automatically generates precise quantitative analysis and text descriptions. The whole process is completed within seconds, significantly improving the efficiency of doctors' diagnosis.
The CE marks means that the software can be commercialized across the European Union under the European Union Medical Device Regulation (MDR), as well as other markets where it is recognized.
